168 related articles for article (PubMed ID: 28730439)
21. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
22. X-Aptamer Selection and Validation.
Lokesh GL; Wang H; Lam CH; Thiviyanathan V; Ward N; Gorenstein DG; Volk DE
Methods Mol Biol; 2017; 1632():151-174. PubMed ID: 28730438
[TBL] [Abstract][Full Text] [Related]
23. Aptamer mediated siRNA delivery.
Chu TC; Twu KY; Ellington AD; Levy M
Nucleic Acids Res; 2006 Jun; 34(10):e73. PubMed ID: 16740739
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
Zhou J; Rossi JJ
BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
[TBL] [Abstract][Full Text] [Related]
25. Aptamer applications for targeted cancer therapy.
Barbas AS; Mi J; Clary BM; White RR
Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124
[TBL] [Abstract][Full Text] [Related]
26. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E; Berezhnoy A; Schrand B
Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
[TBL] [Abstract][Full Text] [Related]
27. Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.
Kruspe S; Giangrande PH
Biomedicines; 2017 Aug; 5(3):. PubMed ID: 28792479
[TBL] [Abstract][Full Text] [Related]
28. Discovering human RNA aptamers by structure-based bioinformatics and genome-based in vitro selection.
Ho B; Polanco J; Jimenez R; Lupták A
Methods Enzymol; 2014; 549():29-46. PubMed ID: 25432743
[TBL] [Abstract][Full Text] [Related]
29. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.
Zhuo Z; Yu Y; Wang M; Li J; Zhang Z; Liu J; Wu X; Lu A; Zhang G; Zhang B
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036890
[TBL] [Abstract][Full Text] [Related]
31. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
[TBL] [Abstract][Full Text] [Related]
32. DNA display of folded RNA libraries enabling RNA-SELEX without reverse transcription.
MacPherson IS; Temme JS; Krauss IJ
Chem Commun (Camb); 2017 Mar; 53(19):2878-2881. PubMed ID: 28220154
[TBL] [Abstract][Full Text] [Related]
33. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
[TBL] [Abstract][Full Text] [Related]
34. [The use of oligonucleotide aptamers in cancer therapy].
Odrzywolski A; Waśko A
Postepy Hig Med Dosw (Online); 2016 May; 70():400-9. PubMed ID: 27180958
[TBL] [Abstract][Full Text] [Related]
35. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
Zhou J; Rossi J
J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
[TBL] [Abstract][Full Text] [Related]
36. Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells.
Jeong H; Lee SH; Hwang Y; Yoo H; Jung H; Kim SH; Mok H
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27863037
[TBL] [Abstract][Full Text] [Related]
37. In silico approaches to RNA aptamer design.
Hamada M
Biochimie; 2018 Feb; 145():8-14. PubMed ID: 29032056
[TBL] [Abstract][Full Text] [Related]
38. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
39. Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells.
Reif R; Haque F; Guo P
Nucleic Acid Ther; 2012 Dec; 22(6):428-37. PubMed ID: 23113765
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA.
Zhu Q; Shibata T; Kabashima T; Kai M
Eur J Med Chem; 2012 Oct; 56():396-9. PubMed ID: 22907035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
